Startups
Newronika
Cologno Monzese, Milan, Italy · Milan, Italy
Newronika S.p.A. is an Italian neurotechnology and medical-device company developing adaptive deep brain stimulation for Parkinson’s disease and researching further neuromodulation applications. Founded in2009 as a spin-off of Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico and the University of Milan, its αDBS/AlphaDBS platform combines implanted neural sensing, a closed-loop stimulation algorithm, a clinician interface and patient remote. The latest commercial system integrates WebBioBank, its cloud platform for longitudinal neural data. The2025 financing announcement describes real-time neural data and machine-learning integration as a development aim, not proof of autonomous clinical decision-making or efficacy for every neurological indication. The current primary directory lists nine leadership/functional members and seven scientific advisers, including ExecutiveChairman KeithCarlton, Co-Founder/CEO/CTO LorenzoRossi and ChiefMedicalOfficer IoannisU.Isaias. The legal issuer is NewronikaS.p.A., VATIT06399770962/REAMI-1890329; headquarters ViaTorquatoTasso1,20093 ColognoMonzese(Milan), with legal address ForoBuonaparte57,20121 Milan. The separately identified NewronikaUSAInc location is a subsidiary and is not treated as another Italian parent headquarters or issuer. The company reports its latest integrated αDBS commercial release CE-marked in the European Economic Area in July2026; its September30,2026 announcement states the first ADVENT pivotal-study participant was implanted September21 in Monza. ADVENT NCT06891781 compares adaptive and conventional DBS in Parkinson’s disease; enrollment is under way, with104participants/up to18sites intended rather than already enrolled. U.S. use remains investigational under an FDA InvestigationalDeviceExemption, with no FDA commercial clearance or approval. Other named conditions on the site remain investigational/emerging applications. Primary financing sources establish EUR1.7M first venture financing in2016, EUR8.4M SeriesA in2019, a separate EICAccelerator grant agreement with exact EUR2,499,999 EU contribution in2023, EUR2M additional EIC equity finance announcedJanuary22,2024 and EUR13.6M SeriesB announcedFebruary13,2025. An additional MichaelJFoxFoundation grant is corroborated but its amount and exact award day are unpublished. Grant commitments, project budgets, earlier selection dates and programme maxima are distinguished from actual disbursements or new equity. Current OrigineSGR is the exact same legal manager historically called InnogestSGR; historic Innogest participation is retained under that canonical manager, rather than creating a namesake investor. Other named buyers require full verified institutional profiles before linkage, and an undisclosed familyoffice is not invented as a company.
Founded 2009
Team
 Alberto PrioriScientific Advisory Board Chair and Co-Founder |
 Andres LozanoScientific Advisory Board Member |
 Aysegul GunduzScientific Advisory Board Member |
 Blayne FleckBusiness Strategy |
Carlo SanfilippoBoard Member (September2025 verified) |
 Claudia PreziosiBusiness Strategy |
 Costanza ContiClinical Affairs Manager |
 Elena MoroScientific Advisory Board Member |
 Guglielmo FoffaniScientific Advisory Board Member |
 Ioannis U. IsaiasChief Medical Officer |
 Jens VolkmannScientific Advisory Board Member |
 Keith CarltonExecutive Chairman |
 Lorenzo RossiCo-Founder, CEO & CTO |
 Marcello CasaliManager - Quality, Regulatory, & Manufacturing |
 Mattia ArlottiVP - Engineering & New Product Development |
 Roshini JainClinical Strategy |
 Sara MarcegliaScientific Advisory Board Member and Co-Founder |